Enables RAGE receptor binding activity; identical protein binding activity; and metal ion binding activity. Involved in several processes, including long-term synaptic potentiation; negative regulation of skeletal muscle cell differentiation; and positive regulation of myelination. Located in extracellular space. Used to study demyelinating disease. Biomarker of several diseases, including bipolar disorder; borna disease; brain disease (multiple); depressive disorder; and sleep apnea. Human ortholog(s) of this gene implicated in Alzheimer's disease; Parkinson's disease; aspergillosis; and schizophrenia. Orthologous to human S100B (S100 calcium binding protein B); PARTICIPATES IN calcium/calcium-mediated signaling pathway; INTERACTS WITH (+)-pilocarpine; (R)-lipoic acid; 1,2-dimethylhydrazine.
[Furosemide results in decreased activity of SLC12A2 protein] affects the reaction [Thioctic Acid inhibits the reaction [Ammonia results in increased secretion of S100B protein]] and Thioctic Acid inhibits the reaction [Ammonia results in increased secretion of S100B protein]
Tetradecanoylphorbol Acetate inhibits the reaction [Trientine inhibits the reaction [S100B protein results in increased expression of AGER protein]] more ...
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA and [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of S100B mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of S100B mRNA
[lard co-treated with Cholesterol and Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of S100B mRNA
anatoxin a inhibits the reaction [Tretinoin results in decreased expression of S100B protein] and Tretinoin results in increased expression of and results in increased secretion of S100B protein
pimagedine inhibits the reaction [Streptozocin results in decreased expression of S100B protein] and pimagedine inhibits the reaction [Streptozocin results in increased expression of S100B protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of S100B mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of S100B mRNA
[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of S100B protein and NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of S100B protein]
[Ethanol co-treated with Corticosterone] results in increased expression of and affects the localization of S100B protein and Corticosterone results in increased expression of and affects the localization of S100B protein
[lard co-treated with Cholesterol and Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of S100B mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of S100B mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of S100B mRNA
[Ethanol co-treated with Corticosterone] results in increased expression of and affects the localization of S100B protein and Ethanol results in increased expression of and affects the localization of S100B protein
[lard co-treated with Cholesterol and Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of S100B mRNA
[Furosemide results in decreased activity of SLC12A2 protein] affects the reaction [Thioctic Acid inhibits the reaction [Ammonia results in increased secretion of S100B protein]] and [Furosemide results in decreased activity of SLC12A2 protein] inhibits the reaction [Ammonia results in increased secretion of S100B protein]
[lard co-treated with Cholesterol and Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in increased expression of S100B mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of S100B mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of S100B mRNA
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA and [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein
[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of S100B protein and NLRP3 protein affects the reaction [[Methionine deficiency co-treated with Choline deficiency co-treated with Dietary Fats co-treated with cyanoginosin LR] results in increased expression of S100B protein]
[Furosemide results in decreased activity of SLC12A2 protein] affects the reaction [Thioctic Acid inhibits the reaction [Ammonia results in increased secretion of S100B protein]] and Thioctic Acid inhibits the reaction [Ammonia results in increased secretion of S100B protein]
[S100B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide and PARP1 gene mutant form inhibits the reaction [S100B protein results in increased secretion of Nitric Oxide]
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100B mRNA
Tetradecanoylphorbol Acetate inhibits the reaction [Trientine inhibits the reaction [S100B protein results in increased expression of AGER protein]] and Tetradecanoylphorbol Acetate inhibits the reaction [Trientine inhibits the reaction [S100B protein results in increased expression of BACE1 protein]]
Catechin inhibits the reaction [S100B protein results in increased abundance of Reactive Oxygen Species] and Quercetin inhibits the reaction [S100B protein results in increased abundance of Reactive Oxygen Species]
Resveratrol inhibits the reaction [Ammonia results in increased secretion of S100B protein] and Resveratrol inhibits the reaction [Nitroprusside results in increased secretion of S100B protein]
SB 203580 inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA] and SB 203580 inhibits the reaction [S100B protein results in increased expression of NOS2 protein]
pimagedine inhibits the reaction [Streptozocin results in decreased expression of S100B protein] and pimagedine inhibits the reaction [Streptozocin results in increased expression of S100B protein]
FPS-ZM1 inhibits the reaction [S100B protein promotes the reaction [Thioacetamide results in increased expression of and results in increased secretion of VEGFA protein]] more ...
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100B mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100B mRNA
veliparib inhibits the reaction [S100B protein results in increased expression of IL1B mRNA] and veliparib inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA]
[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100B mRNA
Effect of endurance exercise training on the expression of GFAP, S100B, and NSE in the striatum of chronic/progressive mouse model of Parkinson's disease.
Systemic markers of inflammation are independently associated with S100B concentration: results of an observational study in subjects with acute ischaemic stroke.
S100B Protein Regulates Astrocyte Shape and Migration via Interaction with Src Kinase: IMPLICATIONS FOR ASTROCYTE DEVELOPMENT, ACTIVATION, AND TUMOR GROWTH.
Association of increased S100B, S100A6 and S100P in serum levels with acute coronary syndrome and also with the severity of myocardial infarction in cardiac tissue of rat models with ischemia-reperfusion injury.
Oral Uncaria rhynchophylla (UR) reduces kainic acid-induced epileptic seizures and neuronal death accompanied by attenuating glial cell proliferation and S100B proteins in rats.
Vitamin D and calcium co-therapy mitigates pre-established cadmium nephropathy by regulating renal calcium homeostatic molecules and improving anti-oxidative and anti-inflammatory activities in rat.
Downregulation of an astrocyte-derived inflammatory protein, S100B, reduces vascular inflammatory responses in brains persistently infected with Borna disease virus.
Treadmill training restores spatial cognitive deficits and neurochemical alterations in the hippocampus of rats submitted to an intracerebroventricular administration of streptozotocin.
S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction.
Neuroprotective effects of caffeic acid phenethyl ester against sevoflurane‑induced neuronal degeneration in the hippocampus of neonatal rats involve MAPK and PI3K/Akt signaling pathways.
